Insider Transactions in Q3 2025 at Ionis Pharmaceuticals Inc (IONS)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2025
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
49,800
-31.07%
|
$3,237,000
$65.26 P/Share
|
|
Sep 30
2025
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
49,800
+23.7%
|
$2,639,400
$53.77 P/Share
|
|
Sep 30
2025
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
57,900
-42.09%
|
$3,763,500
$65.24 P/Share
|
|
Sep 30
2025
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
57,900
+29.62%
|
$3,068,700
$53.77 P/Share
|
|
Sep 30
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
14,827
-20.61%
|
$948,928
$64.68 P/Share
|
|
Sep 30
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
14,827
+17.08%
|
$830,312
$56.78 P/Share
|
|
Sep 29
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
10,473
-15.49%
|
$670,272
$64.54 P/Share
|
|
Sep 29
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,473
+13.41%
|
$586,488
$56.78 P/Share
|
|
Sep 12
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
1,700
-2.89%
|
$108,800
$64.58 P/Share
|
|
Sep 12
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+2.81%
|
$95,200
$56.78 P/Share
|
|
Sep 09
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
21,000
-13.83%
|
$1,344,000
$64.56 P/Share
|
|
Sep 09
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+11.14%
|
$1,218,000
$58.83 P/Share
|
|
Sep 09
2025
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
11,950
-27.24%
|
$740,900
$62.16 P/Share
|
|
Sep 09
2025
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,950
+21.41%
|
$370,450
$31.8 P/Share
|
|
Sep 05
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,000
-6.77%
|
$354,000
$59.6 P/Share
|
|
Sep 05
2025
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
250
-0.78%
|
$15,500
$62.0 P/Share
|
|
Sep 05
2025
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+0.77%
|
$7,750
$31.8 P/Share
|
|
Sep 03
2025
|
Joseph H Wender Director |
SELL
Open market or private sale
|
Indirect |
22,400
-9.33%
|
$1,344,000
$60.14 P/Share
|
|
Sep 03
2025
|
Shannon L. Devers EVP, Chief Human Resources Ofc |
BUY
Exercise of conversion of derivative security
|
Direct |
3,162
+8.23%
|
$110,670
$35.09 P/Share
|
|
Sep 03
2025
|
Shannon L. Devers EVP, Chief Human Resources Ofc |
SELL
Open market or private sale
|
Direct |
3,162
-17.4%
|
$192,882
$61.02 P/Share
|
|
Sep 03
2025
|
Joseph Klein Iii Director |
SELL
Open market or private sale
|
Indirect |
56,000
-100.0%
|
$3,360,000
$60.0 P/Share
|
|
Sep 03
2025
|
Joseph Klein Iii Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
56,000
+40.0%
|
-
|
|
Sep 03
2025
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
203,814
-24.04%
|
$12,228,840
$60.1 P/Share
|
|
Sep 03
2025
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
203,814
+15.46%
|
$7,948,746
$39.14 P/Share
|
|
Sep 03
2025
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,800
+21.22%
|
$1,016,800
$31.8 P/Share
|
|
Sep 03
2025
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
32,800
-36.0%
|
$1,968,000
$60.55 P/Share
|
|
Sep 03
2025
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
19,658
-14.89%
|
$1,179,480
$60.94 P/Share
|
|
Sep 03
2025
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
19,658
+21.64%
|
$1,041,874
$53.77 P/Share
|
|
Sep 03
2025
|
Joseph Loscalzo Director |
SELL
Open market or private sale
|
Direct |
16,000
-30.58%
|
$960,000
$60.15 P/Share
|
|
Sep 03
2025
|
Joseph Loscalzo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+23.42%
|
$384,000
$24.42 P/Share
|
|
Sep 03
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
12,891
-12.69%
|
$786,351
$61.5 P/Share
|
|
Sep 03
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
33,909
-25.03%
|
$2,034,540
$60.62 P/Share
|
|
Sep 03
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,800
+25.67%
|
$2,480,400
$53.77 P/Share
|
|
Sep 03
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
76,850
+34.7%
|
$3,150,850
$41.32 P/Share
|
|
Sep 03
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
76,850
-76.43%
|
$4,687,850
$61.15 P/Share
|
|
Sep 02
2025
|
Joseph H Wender Director |
SELL
Open market or private sale
|
Indirect |
33,600
-6.32%
|
$1,881,600
$56.29 P/Share
|
|
Sep 02
2025
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
11,130
-11.79%
|
$567,630
$51.45 P/Share
|
|
Sep 02
2025
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-11.15%
|
$500,000
$50.37 P/Share
|
|
Sep 02
2025
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
20,000
-12.34%
|
$1,000,000
$50.96 P/Share
|
|
Sep 02
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.34%
|
$245,000
$49.14 P/Share
|
|
Sep 02
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
13,050
-18.6%
|
$704,700
$54.51 P/Share
|
|
Sep 02
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
13,050
+15.68%
|
$417,600
$32.6 P/Share
|
|
Aug 29
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Other acquisition or disposition
|
Direct |
331
+0.58%
|
$8,937
$27.71 P/Share
|
|
Aug 29
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
213
+0.23%
|
$5,751
$27.71 P/Share
|
|
Aug 29
2025
|
Richard S Geary EVP, Chief Development Officer |
BUY
Other acquisition or disposition
|
Direct |
165
+0.18%
|
$4,455
$27.71 P/Share
|
|
Aug 29
2025
|
Brett P Monia Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
189
+0.1%
|
$5,103
$27.71 P/Share
|
|
Aug 29
2025
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Other acquisition or disposition
|
Direct |
166
+0.29%
|
$4,482
$27.71 P/Share
|
|
Aug 22
2025
|
Allene M. Diaz Director |
SELL
Open market or private sale
|
Direct |
1,427
-7.21%
|
$59,934
$42.53 P/Share
|
|
Aug 18
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.67%
|
$430,000
$43.98 P/Share
|
|
Aug 18
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.81%
|
$320,000
$32.6 P/Share
|